Compare WST & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WST | RPRX |
|---|---|---|
| Founded | 1923 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2B | 16.2B |
| IPO Year | N/A | 2020 |
| Metric | WST | RPRX |
|---|---|---|
| Price | $271.13 | $38.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 4 |
| Target Price | ★ $346.78 | $45.75 |
| AVG Volume (30 Days) | 661.3K | ★ 4.0M |
| Earning Date | 10-23-2025 | 11-05-2025 |
| Dividend Yield | 0.33% | ★ 2.29% |
| EPS Growth | ★ 0.17 | N/A |
| EPS | ★ 6.75 | 1.75 |
| Revenue | ★ $3,017,900,000.00 | $2,349,844,000.00 |
| Revenue This Year | $7.01 | $37.13 |
| Revenue Next Year | $6.20 | $1.48 |
| P/E Ratio | $39.63 | ★ $21.92 |
| Revenue Growth | ★ 4.92 | 3.70 |
| 52 Week Low | $187.43 | $24.05 |
| 52 Week High | $348.90 | $41.24 |
| Indicator | WST | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.36 | 46.88 |
| Support Level | $265.39 | $37.88 |
| Resistance Level | $274.56 | $38.93 |
| Average True Range (ATR) | 7.07 | 0.77 |
| MACD | -0.69 | -0.21 |
| Stochastic Oscillator | 31.39 | 20.00 |
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.